TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18761778

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (2.2 g total fatty acids/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borage oil (2.2 g total fatty acids/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (medium-chain fatty acids)
Number of subjects: 0
Study: 17936003

Group type: EXPERIMENTAL
Intervention: Forced-air warmers
Number of subjects: 15

Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 15
Study: 15536429

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 195

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 195
Study: 11303197

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 82
Study: 9121942

Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention, reducing percentage of calories from fat to 21% by Month 4 and maintaining that level for the remainder of the two-year study.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Practical dietary advice on fat reduction and increased intake of grains, fruits, and vegetables.
Number of subjects: 0
Study: 8126815

Group type: EXPERIMENTAL
Intervention: Oral terbutaline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2607128

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 4441859

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia alone (38 cases)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia in combination with chemotherapy (13 cases)
Number of subjects: 51
Study: 31465585

Group type: EXPERIMENTAL
Intervention: Dimethylfumarate (DMF) 720 mg daily
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Fumaric acid esters (FAE)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: DMF and FAE (Week 8 PASI 50/75 responders)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: DMF and FAE (Week 8 PASI ≤ 3 and/or PGA 0-1 responders)
Number of subjects: 671
Study: 31242890

Group type: EXPERIMENTAL
Intervention: Expenditure-specific warning messages
Number of subjects: 45

Group type: COMPARATOR
Intervention: Generic warning messages
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 45
Study: 26951578

Group type: EXPERIMENTAL
Intervention: TC with music (TC + M)
Number of subjects: 18

Group type: COMPARATOR
Intervention: TC in silence (TC + S)
Number of subjects: 18
Study: 26334856

Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone intravenously before CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard CABG surgery without any additional medication (Control)
Number of subjects: 40
Study: 23456585

Group type: EXPERIMENTAL
Intervention: Education based on the Health Belief Model (HBM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study: 22408581

Group type: EXPERIMENTAL
Intervention: High calorie, low nutrient (HCLN) intake
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Video gaming behaviors
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: HCLN intake
Number of subjects: 964
Study: 19225268

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg/day) for 2 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 22
Study: 16859690

Group type: EXPERIMENTAL
Intervention: Emotionally expressive coping
Number of subjects: 342

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 342
Study: 12722963

Group type: EXPERIMENTAL
Intervention: Direct clinician-to-patient feedback discussion on inhaled steroid and beta-agonist use
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard asthma care (Control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Direct clinician-to-patient feedback discussion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 10836281

Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg/day)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/day)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 488

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 488
Study: 9337629

Group type: EXPERIMENTAL
Intervention: Training on means-ends behaviors
Number of subjects: 1

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study: 8409060

Group type: EXPERIMENTAL
Intervention: Albunex 0.08 ml/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Albunex 0.22 ml/kg
Number of subjects: 20
Study: 2875235

Group type: EXPERIMENTAL
Intervention: 45 min bicycling at 60-70% of maximum work capacity (Wmax) three times per week (3/week) for 4 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 45 min bicycling seven times per week (7/week) for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sedentary phase
Number of subjects: 13

Group type: COMPARATOR
Intervention: Run-in phase
Number of subjects: 13
Study: 29681200

Group type: EXPERIMENTAL
Intervention: plasma-derived factor VIII/von Willebrand factor (pdFVIII/VWF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: recombinant factor VIII (rFVIII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of pdFVIII/VWF vs rFVIII
Number of subjects: 0
Study: 26522081

Group type: EXPERIMENTAL
Intervention: Low-Ca group (40 g of milk powder containing 300 mg of Ca and 5 μg of vitamin D)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mid-Ca group (same milk powder additionally fortified with 300 mg of Ca)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-Ca group (same milk powder additionally fortified with 600 mg of Ca)
Number of subjects: 150
Study: 24118636

Group type: EXPERIMENTAL
Intervention: Hepatitis E vaccine Hecolin(®)
Number of subjects: 12409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12409

Group type: EXPERIMENTAL
Intervention: Pre-existing immunity
Number of subjects: 12409
Study: 23019349

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RTA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RTA in patients with toxic TNs
Number of subjects: 40
Study: 20159379

Group type: EXPERIMENTAL
Intervention: Ultrarapid IV hydration (50 mL/kg normal saline for 1 hour)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard IV hydration (50 mL/kg normal saline for 3 hours)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Ultrarapid IV hydration
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard IV hydration
Number of subjects: 88
Study: 17654232

Group type: EXPERIMENTAL
Intervention: Antioxidant-supplemented group (500 mg/day of vitamin E, 30 mg/day of beta-carotene, and for the last 15 days, 1 g/day of vitamin C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antioxidant-supplemented group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 15984138

Group type: EXPERIMENTAL
Intervention: Multi-stage dental health promotion programme
Number of subjects: 0
Study: 11999627

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (other AEDs)
Number of subjects: 24
Study: 10412891

Group type: EXPERIMENTAL
Intervention: 1.5 mg E2 tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2 mg E2V tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.5 mg E2 plus 0.15 mg DSG tablets
Number of subjects: 18
Study: 7751882

Group type: EXPERIMENTAL
Intervention: Eight-drugs-in-1-day chemotherapy without RT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Craniospinal RT and chemotherapy (vincristine, lomustine (CCNU), and prednisone)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Craniospinal RT
Number of subjects: 25
Study: 2268023

Group type: EXPERIMENTAL
Intervention: 16 and 22 gauge cannulae
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 22 gauge Jelco cannulae
Number of subjects: 80
Study: 388396

Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.d.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of tienilic acid 250 mg/day and propranolol 80 mg b.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 16
Study: 30635070

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (six cycles of capecitabine and oxaliplatin)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Historic control group (postoperative adjuvant chemotherapy)
Number of subjects: 14
Study: 29264988

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 35
Study: 25819007

Group type: EXPERIMENTAL
Intervention: Four doses of unpegylated filgrastim (87.5%)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pegylated filgrastim once per cycle (89.4%)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Four doses of unpegylated filgrastim
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pegylated filgrastim once per cycle
Number of subjects: 51
Study: 23955812

Group type: EXPERIMENTAL
Intervention: MMP-9 rs2250889 PR/RR genotype in the training cohort
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: MMP-9 rs17576 RQ/QQ genotype in the training cohort
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: MMP-9 rs2250889 genotype in the validation cohort
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: MMP-9 rs17576 genotype in the validation cohort
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: MMP-9 rs17576 genotype in multivariate analysis
Number of subjects: 421
Study: 22211211

Group type: EXPERIMENTAL
Intervention: Community-based advanced practice nurse (APN) intervention (PATH) with a minimum of one visit per week for one year
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 238
Study: 19363909

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 0
Study: 17389757

Group type: EXPERIMENTAL
Intervention: Peptide inhalation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 24
Study: 15179062

Group type: EXPERIMENTAL
Intervention: Blindfolding for 5 consecutive days (96 hours)
Number of subjects: 13
Study: 11487742

Group type: EXPERIMENTAL
Intervention: DHA supplementation (345 mg/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 9726699

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7520257

Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controlled ventilation to an initial PETCO2 of 3 kPa (22 mmHg) (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controlled ventilation to an initial PETCO2 of 4 kPa (30 mmHg) (Group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controlled ventilation to an initial PETCO2 of 5 kPa (37 mmHg) (Group 4)
Number of subjects: 40
Study: 2731311

Group type: EXPERIMENTAL
Intervention: 8 g magnesium sulfate infused over 4.5 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic sodium chloride infused over 4.5 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard antiemetic regimen (10 mg diazepam and 0.5 mg/kg metoclopramide every 2 h)
Number of subjects: 20
Study: 30260776

Group type: EXPERIMENTAL
Intervention: 10 days of sequential therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid for 5 d, followed by pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for additional 5 d)
Number of subjects: 206

Group type: COMPARATOR
Intervention: 10 days of triple therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid)
Number of subjects: 206

Group type: COMPARATOR
Intervention: 14 days of triple therapy (pantoprazole 40 mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid)
Number of subjects: 206
Study: 27631874

Group type: EXPERIMENTAL
Intervention: Intervention + activity monitoring (INT+)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study: 26202898

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cells (allo-ASC) injected with fibrin glue
Number of subjects: 12
Study: 23953873

Group type: EXPERIMENTAL
Intervention: Hiking (2-3 hikes/week, 2-2.5 hours each for 9 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control period (9 weeks without hiking)
Number of subjects: 20
Study: 21785373

Group type: EXPERIMENTAL
Intervention: 1-month hormone therapy suspension
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: 2-month hormone therapy suspension
Number of subjects: 1405

Group type: COMPARATOR
Intervention: Control group (continued hormone therapy)
Number of subjects: 1405
Study: 18198394

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1471
Study: 15721471

Group type: EXPERIMENTAL
Intervention: Head cooling for 72 h, within 6 h of birth, with rectal temperature maintained at 34‐35 degrees C (n=116)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Conventional care (n=118)
Number of subjects: 234
Study: 12869909

Group type: EXPERIMENTAL
Intervention: Amoxicillin (10 days therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clindamycin (10 days therapy)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 45
Study: 10560998

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Naloxone infusion
Number of subjects: 16
Study: 8826687

Group type: EXPERIMENTAL
Intervention: Life events reported before onset of panic disorder/agoraphobia
Number of subjects: 187
Study: 2050231

Group type: EXPERIMENTAL
Intervention: Dithranol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical 13‐cis‐retinoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinoids
Number of subjects: 0
Study: 6403342

Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 20
Study: 30892000

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28544581

Group type: EXPERIMENTAL
Intervention: MPH XR‐ODT (2 × 30 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference medication (60 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MPH XR‐ODT and Reference medication
Number of subjects: 42
Study: 26564793

Group type: EXPERIMENTAL
Intervention: Maternal health and well-being checklist used by intervention group nurses
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sustained domestic violence screening practices
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Normalization of domestic violence screening
Number of subjects: 123
Study: 25243994

Group type: EXPERIMENTAL
Intervention: Low supervisor-focused interpersonal justice climate
Number of subjects: 0

Group type: COMPARATOR
Intervention: High supervisor-focused interpersonal justice climate
Number of subjects: 0
Study: 22840447

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole
Number of subjects: 229

Group type: COMPARATOR
Intervention: 500 mg mebendazole
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 229

Group type: COMPARATOR
Intervention: mebendazole
Number of subjects: 229
Study: 19826895

Group type: EXPERIMENTAL
Intervention: Iliohypogastric neurectomy and subcutaneous transposition of the spermatic cord
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lichtenstein hernia repair with neurectomy and new procedure
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lichtenstein operation only
Number of subjects: 54
Study: 18021879

Group type: EXPERIMENTAL
Intervention: Current smokers of > or =15 cigarettes per day
Number of subjects: 28236

Group type: EXPERIMENTAL
Intervention: Current smokers of > or =25 cigarettes per day
Number of subjects: 28236

Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 28236

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 28236

Group type: EXPERIMENTAL
Intervention: Current smokers of 1 to 14 cigarettes per day
Number of subjects: 28236
Study: 17493059

Group type: EXPERIMENTAL
Intervention: Behavioral trial
Number of subjects: 65
Study: 12802820

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random effects approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grouped proportional hazards regression model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic logistic regression model
Number of subjects: 0
Study: 11145488

Group type: EXPERIMENTAL
Intervention: Rivastigmine (6-12 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9163263

Group type: EXPERIMENTAL
Intervention: Prilocaine 650 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Prilocaine 500 mg
Number of subjects: 59
Study: 1607520

Group type: EXPERIMENTAL
Intervention: Accelerated 90-min regimen of rt-PA (100 mg total: 15 mg bolus, 50 mg over 30 min, 35 mg over 60 min)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Standard 3-h regimen of rt-PA (100 mg total: 10 mg bolus, 50 mg for the 1st h, 20 mg/h for 2 h)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Accelerated 90-min regimen of rt-PA (100 mg total)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Standard 3-h regimen of rt-PA (100 mg total)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Both groups (Accelerated and Standard)
Number of subjects: 281
Study: 2933951

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 215
Study: 31594738

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to promote CC screening
Number of subjects: 355

Group type: COMPARATOR
Intervention: Referral only (control condition)
Number of subjects: 355
Study: 29987321

Group type: EXPERIMENTAL
Intervention: Early introduction group (EIG) - infants continued to breastfeed while introducing nonallergenic and then 6 allergenic foods
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Standard introduction group (SIG) - followed British infant feeding guidelines (exclusive breastfeeding to around age 6 months)
Number of subjects: 1303
Study: 26588006

Group type: EXPERIMENTAL
Intervention: Electronic medication dispenser (EMD) used for 1 year
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no EMD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electronic medication dispenser (EMD)
Number of subjects: 80
Study: 24616136

Group type: EXPERIMENTAL
Intervention: Training family physicians to deliver a brief intervention during consultations
Number of subjects: 594

Group type: COMPARATOR
Intervention: Usual care only (Control)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Training family physicians to deliver a brief intervention (restricted analysis to patients with excessive substance use at baseline)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Usual care only (Control, restricted analysis to patients with excessive substance use at baseline)
Number of subjects: 594
Study: 22059531

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Eating disorder not otherwise specified-bulimia type (EDNOS-BN)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 135
Study: 19690954

Group type: EXPERIMENTAL
Intervention: H + D (trastuzumab plus docetaxel)
Number of subjects: 107

Group type: COMPARATOR
Intervention: H ‐‐> H + D (trastuzumab monotherapy followed by trastuzumab plus docetaxel)
Number of subjects: 107
Study: 18555937

Group type: EXPERIMENTAL
Intervention: G-ER BID (600 mg at 8 am and 1200 mg at 8 pm)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: G-ER QD (1800 mg at 8 pm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: G-IR TID (600 mg at 8 am, 2 pm, and 8 pm)
Number of subjects: 21
Study: 16307945

Group type: EXPERIMENTAL
Intervention: Excisional biopsy
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Incisional biopsy
Number of subjects: 2182

Group type: EXPERIMENTAL
Intervention: Shave biopsy
Number of subjects: 2182

Group type: COMPARATOR
Intervention: All biopsy types
Number of subjects: 2182
Study: 11907659

Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF) at 0.40 l/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF) at 0.70 l/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF) at 1.10 l/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF) at 0.40 l/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF) at 0.70 l/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF) at 1.10 l/s
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Constant inflation flow (CF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decelerating inflation flow (DF)
Number of subjects: 10
Study: 10396167

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Supportive counselling/psychoeducation (SC)
Number of subjects: 21
Study: 9082759

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 110